Stryker Corporation $SYK Shares Sold by Gabelli Funds LLC

Gabelli Funds LLC decreased its position in shares of Stryker Corporation (NYSE:SYK) by 6.2% during the 1st quarter, Holdings Channel.com reports. The firm owned 76,155 shares of the medical technology company’s stock after selling 5,060 shares during the quarter. Gabelli Funds LLC’s holdings in Stryker were worth $25,024,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in SYK. Brighton Jones LLC raised its position in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after acquiring an additional 609 shares in the last quarter. Schnieders Capital Management LLC. acquired a new stake in Stryker in the 2nd quarter valued at about $205,000. Marshall Wace LLP boosted its position in shares of Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock valued at $2,255,000 after purchasing an additional 77,831 shares in the last quarter. Nebula Research & Development LLC bought a new position in shares of Stryker during the 2nd quarter valued at about $219,000. Finally, HUB Investment Partners LLC acquired a new position in shares of Stryker in the 2nd quarter worth approximately $253,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SYK has been the subject of a number of recent analyst reports. Argus set a $370.00 price objective on shares of Stryker in a research note on Thursday, July 9th. Weiss Ratings downgraded shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. Sanford C. Bernstein set a $410.00 target price on Stryker in a report on Friday, May 1st. Truist Financial reaffirmed a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Finally, Barclays lowered their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $392.52.

Stryker Stock Performance

SYK stock opened at $330.69 on Friday. The firm has a 50 day simple moving average of $314.69 and a 200 day simple moving average of $335.66. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.14. The stock has a market cap of $126.77 billion, a P/E ratio of 38.27, a P/E/G ratio of 2.12 and a beta of 0.77. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the prior year, the company posted $2.84 EPS. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Research analysts anticipate that Stryker Corporation will post 14.99 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is currently 40.74%.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the sale, the vice president owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.